In this issue:
Inhaled treprostinil in pulmonary hypertension due to ILD
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2)
Outcome of hospitalization for COVID-19 in patients with ILD
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma
Efficacy and safety of once-daily singleinhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN)
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced IPF and risk of pulmonary hypertension
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated ILD treated with mycophenolate
Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation
Pirfenidone plus inhaled N-acetylcysteine for IPF
Please login below to download this issue (PDF)